Sanofi: Alzheimer Disease trials
The registry lists 11 Alzheimer Disease studies with Sanofi as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 7Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's DiseaseRecruitingNCT07688213Phase 2
- A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's DiseaseCompletedNCT06343636Phase 1
- Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's DiseaseWithdrawnNCT02667496Phase 2
- Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's PatientsCompletedNCT01485302Phase 1
- Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on DonepezilCompletedNCT01266525Phase 2
- Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's DiseaseTerminatedNCT00602680Phase 2
- Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.CompletedNCT00380302Phase 1/2
- Long-Term Safety Extension With SR57667B in Patients With Alzheimer's DiseaseCompletedNCT00285077Phase 2
- Study of the Effect of SR57667B in Patients With Alzheimer's DiseaseCompletedNCT00285025Phase 2
- Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCompletedNCT00104013Phase 3
- 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCompletedNCT00103649Phase 3